SynthesisBMC musculoskeletal disorders2011
Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response.
Synthesis in BMC musculoskeletal disorders, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 11 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 11 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Mirtazapine for fibromyalgia in adults.The Cochrane database of systematic reviews · 2018Pooled it
- Combination pharmacotherapy for the treatment of fibromyalgia in adults.The Cochrane database of systematic reviews · 2018Pooled it
- Transcutaneous electrical nerve stimulation (TENS) for fibromyalgia in adults.The Cochrane database of systematic reviews · 2017Pooled it
- A systematic review of the effectiveness of policies restricting access to pregabalin.BMC health services research · 2017Pooled it
- Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults.The Cochrane database of systematic reviews · 2017Pooled it
- Topical capsaicin (high concentration) for chronic neuropathic pain in adults.The Cochrane database of systematic reviews · 2017Pooled it
- Gabapentin for fibromyalgia pain in adults.The Cochrane database of systematic reviews · 2017Pooled it
- Antipsychotics for fibromyalgia in adults.The Cochrane database of systematic reviews · 2016Pooled it
- Milnacipran for pain in fibromyalgia in adults.The Cochrane database of systematic reviews · 2015Pooled it
- Pooled it
- Milnacipran for neuropathic pain and fibromyalgia in adults.The Cochrane database of systematic reviews · 2012Pooled it
- Duloxetine use in chronic painful conditions--individual patient data responder analysis.European journal of pain (London, England) · 2014Trial
- Article
- Amitriptyline for fibromyalgia in adults.The Cochrane database of systematic reviews · 2019Review
- Developing and Implementing a Community-Based Model of Care for Fibromyalgia: A Feasibility Study.Pain research & management · 2017Article
- Pregabalin for pain in fibromyalgia in adults.The Cochrane database of systematic reviews · 2016Review
- Oxycodone for pain in fibromyalgia in adults.The Cochrane database of systematic reviews · 2016Review
- Clinical utility, safety, and efficacy of pregabalin in the treatment of fibromyalgia.Drug, healthcare and patient safety · 2016Review
- [Fibromyalgia patients' perceptions of the impact of the disease in the workplace].Atencion primaria · 2015Article
- Work-related outcomes in randomised placebo-controlled pain trials: a systematic review and meta-analysis.Journal of occupational medicine and toxicology (London, England) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundClinical trials in chronic pain often collect information about interference with work as answers to component questions of commonly used questionnaires but these data are not normally analysed separately.
methodsWe performed a meta-analysis of individual patient data from four large trials of pregabalin for fibromyalgia lasting 8-14 weeks. We analysed data on interference with work, inferred from answers to component questions of Fibromyalgia Impact Questionnaire (FIQ), Short Form 36 Health Survey, Sheehan Disability Scale, and Multidimensional Assessment of Fatigue, including "How many days in the past week did you miss work, including housework, because of fibromyalgia?" from FIQ. Analyses were performed according to randomised treatment group (pregabalin 150-600 mg daily or placebo), pain improvement (0-10 numerical pain rating scale scores at trial beginning vs. end), and end of trial pain state (100 mm visual analogue pain scale [VAS]).
resultsComparing treatment group average outcomes revealed modest improvement over the duration of the trials, more so with active treatment than with placebo. For the 'work missed' question from FIQ the change for patients on placebo was from 2.2 (standard deviation [SD] 2.3) days of work lost per week at trial beginning to 1.9 (SD 2.1) days lost at trial end (p < 0.01). For patients on 600 mg pregabalin the change was from 2.1 (SD 2.2) days to 1.6 (SD 2.0) days (p < 0.001). However, the change in days of work lost was substantial in patients with a good pain response: from 2.0 (SD 2.2) days to 0.97 (SD 1.6) days (p < 0.0001) for those experiencing >/= 50% pain improvement and from 1.9 (SD 2.2) days to 0.73 (SD 1.4) days (p < 0.0001) for those achieving a low level of pain at trial end (<30 mm on the VAS). Patients achieving both >/= 50% pain improvement and a pain score <30 mm on the VAS had the largest improvement, from 2.0 (SD 2.2) days to 0.60 (SD 1.3) days (p < 0.0001). Analysing answers to the other questions yielded qualitatively similar results.
conclusionsEffective pain treatment goes along with benefit regarding work. A reduction in time off work >1 day per week can be achieved in patients with good pain responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.